Insider Transactions in Q4 2023 at Akero Therapeutics, Inc. (AKRO)
Insider Transaction List (Q4 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 27
2023
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
5,414
-2.84%
|
$129,936
$24.0 P/Share
|
|
Dec 27
2023
|
Jonathan Young Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,414
+2.76%
|
$32,484
$6.36 P/Share
|
|
Dec 14
2023
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
597
-0.76%
|
$11,940
$20.76 P/Share
|
|
Dec 14
2023
|
William Richard White Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
611
-1.2%
|
$12,220
$20.76 P/Share
|
|
Dec 14
2023
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
1,628
-0.29%
|
$32,560
$20.76 P/Share
|
|
Dec 14
2023
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
543
-0.29%
|
$10,860
$20.76 P/Share
|
|
Dec 14
2023
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
514
-0.28%
|
$10,280
$20.76 P/Share
|
|
Dec 11
2023
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
7,405
-1.32%
|
$148,100
$20.02 P/Share
|
|
Dec 11
2023
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,405
+1.31%
|
$44,430
$6.36 P/Share
|
|
Dec 08
2023
|
Jonathan Young Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,497
+14.9%
|
-
|
|
Dec 08
2023
|
William Richard White Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,497
+38.94%
|
-
|
|
Dec 08
2023
|
Patrick Lamy Senior VP, Commercial Strategy |
BUY
Grant, award, or other acquisition
|
Direct |
18,570
+50.0%
|
-
|
|
Dec 08
2023
|
Timothy Rolph Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,497
+15.07%
|
-
|
|
Dec 08
2023
|
Catriona Yale Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,497
+29.28%
|
-
|
|
Dec 08
2023
|
G. Walmsley Graham |
BUY
Open market or private purchase
|
Indirect |
100,000
+6.07%
|
$1,900,000
$19.83 P/Share
|
|
Dec 08
2023
|
Andrew Cheng President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
91,541
+14.21%
|
-
|
|
Dec 08
2023
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
12,873
-2.72%
|
$257,460
$20.01 P/Share
|
|
Dec 08
2023
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,873
+2.64%
|
$77,238
$6.36 P/Share
|
|
Dec 07
2023
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
6,700
-1.43%
|
$134,000
$20.02 P/Share
|
|
Dec 07
2023
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,700
+1.41%
|
$40,200
$6.36 P/Share
|
|
Dec 01
2023
|
G. Walmsley Graham |
BUY
Open market or private purchase
|
Indirect |
50,000
+6.67%
|
$800,000
$16.99 P/Share
|
|
Nov 30
2023
|
G. Walmsley Graham |
BUY
Open market or private purchase
|
Indirect |
50,000
+7.14%
|
$800,000
$16.9 P/Share
|
|
Nov 17
2023
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
30,000
-16.38%
|
$420,000
$14.68 P/Share
|
|
Oct 02
2023
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
25,000
-1.05%
|
$1,200,000
$48.35 P/Share
|
|
Oct 02
2023
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+4.89%
|
$150,000
$6.36 P/Share
|
|
Oct 02
2023
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
490
-0.27%
|
$24,990
$51.1 P/Share
|
|
Oct 02
2023
|
Jonathan Young Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
490
+0.27%
|
$10,290
$21.1 P/Share
|